We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A large co‐operative biological and clinical study to better understand and improve treatment of the rare t(8;16)(p11;p13) acute myeloid leukaemia.
- Authors
Becker, Michael W.; Angelucci, Emanuele
- Abstract
A large co-operative biological and clinical study to better understand and improve treatment of the rare t(8;16)(p11;p13) acute myeloid leukaemia Acute myeloid leukaemia (AML) with t(8;16)(p11;p13) is a rare AML subtype involving exon 15 or 16 of the I MYST3 i gene [K(lysine) acetyltransferase 6A ( I KAT6A i )] on chromosome 8p11 and exons 3-8 of cAMP response element-binding protein (CREB)-binding protein (CREBBP, CBP) on chromosome 16p13. Hierarchical clustering of RNA expression data from a subset of MYST3-linked AML samples showed that most MYST3-linked AMLs grouped together and constituted a homogeneous subgroup of AML. Consistent with prior reports, t(8;16)(p11;p13) AML is rare (0-2 % of AML cases) and is over-represented in therapy-related AML (1-6% of t-AML cases), with a median overall survival (OS) of 4-7 months.
- Publication
British Journal of Haematology, 2021, Vol 192, Issue 5, p800
- ISSN
0007-1048
- Publication type
Academic Journal
- DOI
10.1111/bjh.17332